267 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1769)
- Addiction (18)
- Allergy, Asthma, & Immunology (13)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (29)
- Blood Disorders (33)
- Bone & Muscle (10)
- (-)
Cancer
(585)
- Bladder Cancer (16)
- Brain Cancer (12)
- Breast Cancer (65)
- Gastrointestinal (10)
- Gynecologic Cancer (30)
- Head and Neck Cancer (4)
- Kidney Cancer (7)
- Leukemia (64)
- Liver Cancer (5)
- Lung Cancer (58)
- Lymphoma (24)
- Multiple Myeloma (24)
- Pancreatic Cancer (6)
- Prostate Cancer (27)
- Sarcoma (23)
- Skin Cancer (26)
- Solid Tumors (36)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (50)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (53)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (164)
- Nutrition (6)
- Obesity (10)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (102)
- Psychiatric Disorders (67)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (47)
- Urology (4)
- Vascular Conditions (10)
Displaying 201 - 400 of 588
Condition: Cancer / Prostate Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses your testosterone) given prior to surgery can decrease the chance that your cancer will come back compared to degarelix alone. People who usually have this type of prostate cancer usually do not receive any additional therapy prior to surgery.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to assess the safety and effectiveness of giving anastrozole, palbociclib, trastuzumab, and pertuzumab to women with hormone receptor-positive, HER2-positive metastatic breast cancer. This combination of medications represents an all-biologic approach and avoids chemotherapy as first-line treatment of this disease.
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this clinical research study is to evaluate the safety (any good or bad effects) of CYNK-001 and to assess the effects of CYNK-001 on your Acute Myeloid Leukemia (AML). Also, the study plans to determine the maximum tolerated dose (highest safe dose) of CYNK-001 and assess whether CYNK-001 can eliminate your residual (leftover) disease.…
A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the effectiveness of a new investigational drug, PTC596, used in combination with dacarbazine, for the treatment of locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma, a type of soft tissue sarcoma. The purpose of this study is to evaluate whether adding PTC596 to dacarbazine is safe…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to explore how the combination of the study drugs affects tumors and general health. The study drugs are BMS-986253 and nivolumab. Participants will be given different doses of BMS-986253 and nivolumab to test how safe they are in humans. This is the first study in which BMS-986253 is being given in combination with nivolumab.
Condition: Cancer / Pancreatic Cancer
Investigator: Gulam Manji, MD, PhD
Status: Closed
The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment.
Condition: Cancer
Investigator: Benjamin Izar, MD
Status: Closed
The main purposes of this research study are: to find a safe and tolerated dose of the study drug COM701 alone and in combination with nivolumab; and to measure the amount of COM701 that is in the blood at different times after it is given. This study is for people with advanced cancer (solid tumor) that no longer responds to standard approved therapies.
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known as T cells. The T cells in PBCAR269A came from people who have…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This is a Phase 1 study (the first time this treatment is being tested in humans) of an anti-cancer study drug called as PF-07225570. This study drug works on stimulating certain cells in the immune system. The study will test different doses that increase (dose escalation) and at the appropriate time, additional patients will be enrolled to evaluate this…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test the investigational drug, DS-7300a, for the first time in humans. DS-7300a is an antibody-drug conjugate (ADC) being developed as an anti-cancer agent. ADCs are made up of a monoclonal antibody chemically linked to a drug. The monoclonal antibody binds to specific proteins or receptors found on certain types of cells, including cancer…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to determine the highest dose of the study drug that can be given safely to people with certain cancers. The study will also look at how effective the study drug is in treating certain cancers. The study drug is PLX2853. The participants in this study will be the first people to receive PLX2853.
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The main purpose of this study is to determine the safety of administering an investigational new drug (referred to as INT230-6 or the study drug) directly into multiple superficial (you can feel them with touch) and deep tumors (such as those within the body or inside an organ e.g. the liver). Investigational means that INT230-6 has not yet been approved…
Condition: Cancer / Skin Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer).
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
In Phase 1b, the purpose is to learn how well patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) tolerate the treatment when PLX2853 is added to ongoing treatment with abiraterone acetate and prednisone. We are looking for the highest dose of PLX2853 that can be given safely to patients with your type of disease who are already on…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
This study is being done to evaluate the safety and usefulness of the study drug, AG-881, as compared to placebo (a medically inactive substance) in residual or recurrent non-enhancing Grade 2 glioma (a type of brain cancer) that has a mutation in the IDH1 or IDH2 metabolic enzyme (a substance produced by the body to assist in breaking down chemicals).…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The purpose of the study is to test the safety of an investigational study drug called BMS-986249. BMS-986249 will be given alone and in combination with nivolumab. This study will investigate how patients with advanced solid tumors tolerate these drugs. The study will identify the highest dose or most suitable dose of BMS-986249 alone and in combination…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this research study is to test how safe and how well an investigational drug known as ONC201 works in treating high grade glioma (a type of brain cancer). The FDA (the U.S. Food and Drug Administration) has not approved ONC201 as a treatment for this condition.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to determine whether there is clinical benefit to continue therapy beyondprogression for metastatic or unresectable breast cancer. The treatment that is being investigated in this clinical trial, ribociclib (LEE011), is part of a family of oral medications (pills) that are called Cyclin Dependent Kinase 4 and 6 inhibitors, which…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out if an investigational drug, called ADP-A2M4, is safe and how well it works in attacking Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) cancer cells. The study involves taking certain types of immune cells from the blood, called T cells, and changing them in a laboratory before putting them back into the…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this research study is to see how effective durvalumab andtremelimumab is in patients with early stage non-small cell lung cancer (NSCLC). A a special blood test will be done to see if subjects have circulating tumor DNA (ctDNA) in their blood. ctDNA are pieces of genetic material shed from the tumor cells that can be detected in the blood,…
Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Closed
The purpose of the study is to determine whether ablation, which is the removal or destruction of a tumor (through SBRT and/or surgical resection of all known metastases) in oligometastatic breast cancer patients improves progression-free survival (PFS) and overall survival (OS).
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the combined treatment, using the drugs cetuximab and avelumab as well as avelumab by itself. Avelumab is a drug that works by triggering the immune system so it can try to attack the cancer again. Avelumab works in a similar way to cemiplimab, which is the usual drug for treatment of your…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to find out if you can take part in one or more of the treatment studies sponsored by Immatics. The "treatment studies" involve adoptive cellular therapy (ACT), a type of therapy in which T cells (a type of immune cell) are given to a participant to help the body fight diseases, such as cancer. If your tumor…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to learn about the study drug BDC-1001 in patients with HER2-expressing tumors. Researchers will be studying the use of BDC-1001 alone as well as in combination with Pembrolizaumab. This study will help researchers learn if the study drug can help with HER2-expressing tumors and how people respond to the drug. The researchers…
Condition: Cancer / Breast Cancer
Investigator: Diana Martinez, MD
Status: Closed
Paclitaxel is frequently used to treat breast cancer, but it can also cause neuropathy where the nerves of the hands and feet stop working properly. The symptoms of neuropathy can include pain, numbness, and difficulty with everyday activities like walking or typing. Paclitaxel-induced neuropathy is common and there are few treatment options. Our study will…
Condition: Cancer / Breast Cancer
Investigator: Katherine Crew, MD
Status: Closed
This research study involves receiving an experimental drug referred to as ZN-c5. This is the first study in humans using ZN-c5. The purpose of this research study is to test the safety of ZN-c5 at different dose levels. This study is designed to find out what effects, good and/or bad, ZN-c5 has on participants with breast cancer. Participants in both…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This research study is evaluating an investigational drug, called cirmtuzumab, in combination with astandard drug, called ibrutinib (Imbruvica), as a possible treatment for patients with CLL/SLL or MCL. All cells in the body receive signals to grow and survive, but sometimes these signals get out of control, causing too much cell growth. When the growth of…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The primary purpose of this research study is to learn the safety and tolerability of the investigational drug, XmAb 22841 when given alone or in combination with another drug called pembrolizumab. You will be assigned to either receive XmAb22841 alone or in combination with pembrolizumab and you will know what treatment you are receiving. This study will…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
GEN-011 is an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, the cancer proteins that are already recognized by the patient's T cells are found. Then, immune cells that recognize these cancer proteins…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this study is to test the effectiveness and safety of an experimental drug known as HPN424 (also known as study drug) in patients with advanced prostate cancer. This drug has been tested in animals but not yet in people. This study tests different doses of HPN424. We want to find out how good the drug is at treating prostate cancer. We also…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the study is to evaluate the effectiveness (how well the drug works) of the investigational drug called bempegaldesleukin when combined with drug nivolumab in comparison with nivolumab alone after complete resection (removal of all sites of known disease) of melanoma in participants at high risk of cancer returning after surgery (recurrence).
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The experimental drug being investigated in this study is called rucaparib. Rucaparib is being developed by Clovis Oncology, Inc. (the Sponsor), a biopharmaceutical company with headquarters in the United States (US). Rucaparib (trade name: Rubraca) is a medicine that is approved in the European Union (EU) and the US for use in certain types of ovarian…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is a phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational treatment to learn whether the intervention works in treating a specific disease. Investigational means that the intervention is being studied. The Food and Drug Administration (FDA) has approved Nivolumab as treatment for…
Condition: Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of the study is to evaluate the tolerability of a ketogenic diet in conjunction with metformin in people with malignant glioma. The study doctors will try to determine if maintaining the ketogenic diet with metformin will have any effect on your tumor.
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
The purpose of this study is to identify if blood sugar elevations during chemotherapy may be related to the development of side effects from chemotherapy. This study will help us find out if blood sugar goes up during the course of chemotherapy, and if so, for the amount of time the blood sugar is elevated after a chemotherapy treatment. Results of this…
Condition: Skin Cancer / Melanoma
Investigator: Mariam El-Ashmawy, MD, PhD
Status: Closed
This research study is a phase II clinical trial that will study the combination of adjuvant nivolumab and ipilimumab for the treatment of adult subjects with completely treated high-risk ocular melanoma. This study is being done to see if the combination of the study drugs is safe and effective in preventing the return of their cancer. If you are eligible…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has come back after radiation and chemotherapy. Safety and how well you can tolerate the drug will be determined on the basis of physical exams, laboratory tests,…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
The main purpose of the study is to determine at what dose the study drug (ASP1951) is safe and tolerated and how it is processed in the blood of subjects with tumors that cannot be removed (unresectable) or has spread (metastasized) to a different part of the body. When the safe dose is identified, it will be used to evaluate if the study drug treatment…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery. This study will allow the researchers to know whether treatment with MK-3475 (pembrolizumab) is better, the same, or worse…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the study is to learn if it is safe to give genetically changed T cells (IMA201) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of IMA201 and if the…
Condition: Cancer
Investigator: Ran Reshef, MD
Status: Closed
The goal of the overall study is to learn if it is safe to give genetically changed T cells (IMA202) in combination with standard of care chemotherapy (fludarabine and cyclophosphamide) and IL-2 (aldesleukin) to patients with melanoma solid tumors that have grown or returned after being treated. Researchers also want to learn about possible side effects of…
Condition: Cancer / Gastrointestinal
Investigator: Rachael Safyan, MD
Status: Closed
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
Condition: Psychiatric Disorders / PTSD
Investigator: Franklin Schneier, MD
Status: Closed
We are currently enrolling individuals with post-traumatic stress disorder (PTSD) to participate in this research study. The purpose of this research study is to evaluate the effectiveness of an investigational medication, brexpiprazole, for PTSD. Eligible participants will be randomly assigned to receive either brexpiprazole, sertraline (also known as…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug, BI 1387446, given alone or combined with the study drug, BI 754091, in subjects with different types of advanced cancer. BI 1387446 will be injected directly into at least one tumor site. BI 754091 will be given by intravenous (IV) infusion, which is a slow injection of the…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to test the safety of a study drug called AMG 232 given with radiation in patients with soft tissue sarcoma (STS) prior to surgery. The AMG 232 is investigational. It has been tested in other cancers but not yet in sarcoma. AMG 232 has not been tested using the dosing schedule in this study and it has not been tested with…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
You are being asked to participate in this study because you have been diagnosed with a progressive desmoid tumor. The purpose of this study is to see if the study drug, called AL102 (referred to from now on as the study drug), is safe and effective in people with progressive desmoid tumors. The study will also look at how your body responds to the study…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find out what dose of pacritinib is safest and works best for participants. Pacritinib is an experimental drug, which is a drug that is being tested and is not currently approved by the Food and Drug Administration (FDA) in the US. The study will be conducted at about 85 study clinics in North America, Europe, Israel and…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study will learn more about the drug, XmAb20717. XmAb20717 is designed to activate your own cells to kill your tumor. The primary purposes of this research study are to: determine the safety and tolerability of XmAb20717, see if XmAb20717 works in treating specific tumors , learn about the side effects from XmAb20717. Cancers include:…
Condition: Cancer / Solid Tumors
Investigator: Brian Henick, MD
Status: Closed
BioAtla (the sponsor of the clinical trial) is studying BA3021 as a potential treatment for varieties of cancers including but not limited to lung, triple negative breast cancer and soft tissue sarcoma. The purpose of this research study is to test the safety of different doses of BA3021 and to find out what effects, good and/or bad, it has on the body and…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This primary purpose of this study is to find the recommended dose of LGK974 and PDR001 that can be safely given to adult patients who have advanced metastatic pancreatic cancer, or triple negative breast (TNB) cancer, or melanoma, lung squamous cell cancer, esophageal squamous cell cancer, cervical squamous cell cancer, or head and neck squamous cell…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This study is for patients with prostate cancer and that require treatment because their disease is now growing. The purpose of this study is to see whether immunotherapy with nivolumab added to degarelix or nivolumab and BMS-986253 added to degarelix is safe and can decrease the chance that the cancer will come back. Degarelix is a standard of care drug…
Condition: Cancer / Kidney Cancer
Investigator: Mark Stein, MD
Status: Closed
This study will test whether cabozantinib in combination with nivolumab plus ipilimumab is more effective (works better) than nivolumab plus ipilimumab alone in treating patients with advanced kidney cancer who have not received prior treatment for their cancer. This study will also examine how safe cabozantinib is in combination with nivolumab plus…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This research study will investigate an experimental, unapproved drug that will be given two different ways; as an injection in the bladder wall after bladder tumor resection surgery (or TURBT) and then as an intravesical instillation (fluid inserted in the bladder by catheter) right after the injection. The purpose of this study is to find the dose which…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to: Test if the lifespan of study participants is increased when uproleselan is added to standard chemotherapy medicines compared to standard chemotherapy alone; test if the number of study participants achieving disease remission is increased when uproleselan is added to standard chemotherapy medicines compared to standard…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to test the good and bad effects of the drug called CB-839 HCl (telaglenastat). CB-839 HCl (telaglenastat) could shrink your cancer, but it could also cause side effects. The study doctors hope to learn if the study drug will help control the disease in patients with advanced cancer with changes in specific genes. We don't…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to compare any good and bad effects of using olaparib and atezolizumab in combination compared to olaparib alone. The use of olaparib alone or in combination with atezolizumab could shrink your cancer but could also cause side effects. This study will allow the researchers to know whether the combination approach is better, the…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects who have been diagnosed with multiple myeloma, a cancer of plasmacells (a type of immune cell that produce antibodies) in the bone marrow, that has returned (relapsed) or has not responded (refractory) to your most recent treatment regimen.The subject's disease has also progressed after prior treatment with…
Condition: Cancer / Solid Tumors
Investigator: Mark Stein, MD
Status: Closed
The main purpose of this study is to learn more about the study drug called LY3321367. The study wants to know more about the following: The safety of LY3321367 alone and in combination with another drug called LY3300054 and any side effects you might have Whether LY3321367 is tolerable when taken alone and in combination with LY3300054. How much…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for patients with recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). This study will test the safety of an experimental anti-cancer drug (MEDI4736). MEDI4736 is an antibody (a protein produced by the defense system of the body immune system) that has been made in the laboratory. MEDI4736 boosts the ability of your…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The LIGHT study is a clinical research study for women who have been diagnosed with ovarian cancer. The purpose of the study is to evaluate the safety and effectiveness of an investigational drug in women with this type of cancer, using genetic information to evaluate tumors.
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination of Lenalidomide and Dexamethasone to treat multiple myeloma.
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to test the safety of the study drugs and how well your body tolerates it. The study will also test how well the study drugs work to slow down the growth of you tumor or stop your cancer. The study drugs are Cergutuzumab Amunaleukin and Atezolizumab. Atezolizumab is FDA approved for the treatment of patients with metastatic non-…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
This study is for patients with AML or myelodysplastic syndrome (MDS), SCLC ( other solid tumors, such as endocrine tumors or Myelofibrosis. In this research study we are going to determine how safe and well tolerated the study drug INCB059872 is in subjects/research participants with those types of cancer. Other reasons for this study are to study the…
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to determine if denosumab treatment affects the rate of growth of the cells in the ends of the fallopian tubes compared to receiving no treatment in premenopausal BRCA1/2 mutation carriers.
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without the subjects cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose is to study the safety and the effect of AB122, AB154, and AB928 in participants with stage IV non-small cell lung cancer. Researchers will study the treatment response of AB122 alone as well as in combination with AB154 and AB928. There are three possible groups a participant can be randomly assigned to. Group 1 will include AB122 alone, Group…
Condition: Cancer / Breast Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to identify the doses of spartalizumab (PDR001) with LAG525 in combination with either NIR178, capmatinib (INC280), MCS110 or canakinumab (ACZ885) that can be given safely. The study will also test how well spartalizumab (PDR001) with LAG525 in combination with either NIR178, capmatinib (INC280), MCS110 or canakinumab (ACZ885)…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to evaluate the safety, and effectiveness of ABT-199 in combination with decitabine and ABT-199 in combination with azacitidine in subjects who have not been treated for their AML. In addition, substances (biomarkers) found in the blood and bone marrow that may indicate the effects or progress of the leukemia and the activity of…
Condition: Cancer / Pancreatic Cancer
Investigator: Karie D. Runcie, MD
Status: Closed
The purpose of this study is to find out which doses of talimogene laherparepvec (T-Vec) can be given safely to patients with pancreatic cancer that is either too big to be taken out by surgery or has spread to other parts of the body. The study will also see if T-Vec can cause tumor shrinkage or prevent its growth. To find out which doses are safe, all…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
This study is being done to determine if adding the investigational drugs (TSR-042 and niraparib) to standard of care treatment delays or prevents ovarian cancer recurrence (prevents the ovarian cancer from coming back).
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
This study is for adult subjects with head and neck cancer (oral cavity, oropharynx middle part of the throat, hypopharynx bottom part of the throat, or larynx part of throat between the base of the tongue and the windpipe) that has either returned after treatment (recurrent) or is newly diagnosed. If newly diagnosed, the cancer must be metastatic,…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this trial is to determine whether the study drug, CX-839, reduces tumor size in patients with metastatic triple negative breast cancer when it is used in combination with the standard breast cancer treatment. CX-839 blocks the activity of a certain molecule that is overproduced by some cancer cells.
Condition: Cancer / Gynecologic Cancer
Investigator: Ana Tergas, MD
Status: Closed
AstraZeneca AB (AstraZeneca) is doing this research to find out if durvalumab, when given with chemoradiotherapy will help to treat cervical cancer.
Condition: Cancer / Leukemia
Investigator: Richard Carvajal, MD
Status: Closed
This study is for patients with Acute Myeloid Leukemia (AML). The purpose of this study is to determine if decitabine plus JNJ-56022473 can be safely combined and is active for your disease. The study drugs used in this study are JNJ-56022473, an experimental drug and DACOGEN ( also known generic as decitabine), a drug already used to treat your type of…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The main goal of this study is to find out about how duvelisib acts in patients with CLL/SLL who were previously treated with a BTKi (Bruton Tyrosine Kinase inhibitor - commercially available ibrutinib or another investigational BTKi). Duvelisib is an investigational drug, meaning that it is not FDA approved, designed to try to stop cancer growth by…
Condition: Cancer
Investigator: Matthew Ingham, MD
Status: Closed
This is a research study to test a drug MK-1454 that has not been approved for sale. Pembrolizumab (MK-3475) has been approved for use in certain types of melanoma, lung cancer, and head and neck cancer however it has not been approved for lymphoma. The purpose of this study is to test the safety and tolerability of the research study drug MK-1454 and to…
Condition: Cancer / Breast Cancer
Investigator: Melissa Accordino, MD
Status: Closed
This a Phase III study designed to compare the efficacy and the safety of the triplet combination of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety of the combination of the experimental drugs called atezolizumab and guadecitabine (not yet approved by the U.S. Food and Drug Administration FDA or any other regulatory authority outside the United States) to find out what effects, good or bad, the combination of atezolizumab and guadecitabine has on patients…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to identify the best dose of the study drugs that can be safely given to patients with cancer. The study will also evaluate how well the study drugs work in patients with cancer. The study drugs are LAG525 and PDR001. LAG525 will be given alone or in combination with PDR001.
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
This is a phase 1/1b research study for adults with a diagnosis of an advanced solid tumor for which there are no standard therapies beyond those that may have already been received. This study involves an investigational (experimental) drug called MGCD516. Investigational means that MGCD516 is not approved by the U.S. Food and Drug Administration (FDA).…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
The purpose of this study is to determine whether treatment with sacituzumab govitecan could provide a better response and improve survival (the amount of time you live without your cancer growing) than other forms of cancer treatment (either Eribulin, Capecitabine, Gemcitabine, Vinorelbine).
Condition: Cancer / Uveal Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of the treatment part of the study is to find out what effects drug crizotinib has, good and/or bad on people with "high risk" uveal melanoma after surgery or radiation for the eye. It is thought that giving crizotinib to patients with "high risk" uveal melanoma can lower the chance the cancer will come back. Uveal melanoma…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
This research study is investigating a new treatment for cancer that uses your immune system (a type of white blood cell called T cells or T lymphocytes) to try to attack your cancerous cells. T cells fight infections, and may attack cancer cells, in some cases. Currently, your T cells may not able to attack your cancerous cells. The use of these modified T…
Condition: Cancer / Lymphoma
Investigator: Owen O'Connor, MD, PhD
Status: Closed
This study will test the standard R-CHOP21 against R-CHOP21 plus lenalidomide. The purpose is to see whether adding lenalidomide works better and is as safe as R-CHOP by itself. This study is only for patients with ABC type DLBCL who have not yet been treated. Lenalidomide is not approved for use in DLBCL. Its use in this disease is experimental. In this…
Study of Drug that May Reduce Risk of Blood Clot Development in Cancer Patients Who Are Able to Walk
Condition: Cancer
Investigator: David Diuguid, MD
Status: Closed
The purpose of this study is to see if rivaroxaban is useful in reducing the risk of patients developing blood clots while undergoing cancer treatment. The safety of rivaroxaban will also be studied. Cancer diagnoses include: pancreas, lung, stomach, colon, rectum, bladder, breast, ovary, renal, or lymphoma.
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This research study is testing two potential new drugs called AB928 and AB122. AB928 is an investigational drug that has been shown in animal studies to improve the functioning of the immune system, without causing any immune effects on its own. This research study will help us understand whether AB928, the study drug, can be safely given in combination…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
This study is being done to see how well tolerated the investigational drug TGR-1202 is in comparison to other similar therapeutics agents in treating patients with chronic lymphocytic leukemia (CLL).
Condition: Cancer / Breast Cancer
Investigator: Eileen Connolly, MD, PhD
Status: Closed
The main purpose of this clinical trial is to study women like you who have cancer cells in the lymph nodes at the time that the breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes. This study asks 1) if, after lumpectomy, radiation to the breast and lymph nodes will be better than radiation only…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
Test the safety and effectiveness of the research study drug, pembrolizumab (MK-3475) in combination with chemotherapy, compared to chemotherapy plus placebo (a look-alike drug with no active ingredients) in women with persistent, recurrent, or metastatic cervical cancer. To test if adding pembrolizumab (MK-3475) to standard chemotherapy improves survival…
Condition: Cancer
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to assess how safe and well tolerated study drugs, INCB24360 and nivolumab, are given in combination in patients who have advanced or metastatic solid tumors. The study will also assess how well INCB24360 in combination with nivolumab works in preventing disease progression in patients with melanoma (MEL), non-small cell lung…
Condition: Cancer
Investigator: Mark Stein, MD
Status: Closed
The purpose of this clinical trial is to evaluate safety of the trial treatment, its effects on the immune system and on urothelial cancer. The trial treatment includes INO-5401 + INO-9012 delivered by electroporation in combination with TECENTRIQ (Atezolizumab). INO-5401 + INO 9012 is a DNA based therapy that has been created in a lab using the DNA…
Condition: Cancer
Investigator: Alice Lee, MD
Status: Closed
The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United…
Condition: Cancer / Solid Tumors
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an open-label, multicenter phase 1/2 study. The study is designed in two parts, the first is designed to evaluate the safety of the study drug ulocuplumab in combination with nivolumab in subjects with small cell lung cancer (SCLC) and pancreatic adenocarcinoma (PAC). Subjects will receive a low dose of ulocuplumab in combination with…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
The purpose of this study is to measure the effectiveness and safety of an investigational drug called "alovicidib" in combination with cytarabine and daunorubicin in the treatment of AML. Investigational means that this drug has not been approved by the FDA. Cytarabine and daunorubicin are both standard of care treatments for patients with AML.…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to find out if the experimental product, axicabtagene ciloleucel, in combination with either rituximab or lenalidomide is safe and effective in treating lymphoma. Kite Pharma, Inc., (Kite) is the sponsor of this study. The sponsor is funding this research study and has also designed the trial. The sponsor is testing an…
Condition: Cancer
Investigator: Mark Frattini, MD, PhD
Status: Closed
The purpose of this study is to identify the most appropriate dose that can be safely administered and that can have an effect on haematological cancer cells. BAY 1251152 works by obstructing a protein in your bodys cells called positive transcription elongation factor b (PTEFb) / cyclin-dependent kinase 9 (CDK9) pathway, which plays a role in the growth of…
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this research study is to assess the feasibility of performing hereditary breast and ovarian cancer genetic testing in the oncology clinic and to examine the knowledge and attitudes of hereditary breast and ovarian cancer genetic testing among breast and ovarian cancer patients before and after receiving the results of genetic testing. We…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this trial is to evaluate the safety of CB-839 in combination with nivolumab for patients with advanced/metastatic clear cell Renal Cell Carcinoma (ccRCC), melanoma, and Non-Small Cell Lung Cancer. CB-839 is a drug designed to stop cancer growth by blocking glutaminase activity. Glutaminase is an enzyme in the body that is overproduced by…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The researchers hope to study the effectiveness of an investigational drug called AL3818 in people who have metastatic (meaning their disease has spread) or advanced ), specifically alveolar soft partsarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS). The main purpose of the study isto learn the percentage of patients that respond to treatment…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to find if PTC299 is safe to treat people with relapsed/refractory acute myeloid leukemia (AML) as well to determine the dose of PTC299 that can be given without causing severe side effects. AML is a cancer of the blood and bone marrow (spongy tissue inside bones where blood cells are made). PTC299 is being developed to…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to see if study drug AZD9291 is effective in treating non-small cell lung cancer (NSCLC) and if so, how it compares with chemotherapy. Only patients with NSCLC that has been confirmed as having the EGFR mutation are eligible to participate. Before patients can participate in the main study a tumor sample will be taken to check…
Condition: Cancer
Investigator: Dawn Hershman, MD
Status: Closed
Aim 1: To describe the perceptions and experiences of CIPN by patients. 1. To describe the terminology used by patients to describe CIPN.; 2. To describe the effects that CIPN has on patients' day-to-day quality of life.; 3. To describe how patients communicate with their healthcare providers about CIPN, and what barriers may interfere with this…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to determine if high-dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600. The time frame for the study is approximately 2 years.
Condition: Cancer / Pancreatic Cancer
Investigator: Paul Oberstein, MD
Status: Closed
This research study is being conducted to see if a new treatment using a study drug called Olaparib given after platinum based chemotherapy treatments can reduce the risk of pancreatic cancer from growing back. Participants will receive either Olaparib or placebo (no contains active medication) and will stay on the research study for as long as they are not…
Condition: Cancer
Investigator: Jason Wright, MD
Status: Closed
Atezolizumab is an antibody that affects your immune system by blocking the PD L1 pathway. An antibody is a large, Y-shaped protein used by your body's immune system to identify and kill foreign objects, such as bacteria, viruses, and tumor cells. The PD L1 pathway is involved in the decrease of your body's natural immune response to fight…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of the study is to evaluate the safety and tolerability of BAY 1251152 in patients with any type of solid tumors or non-indolent non-hodgkins lymphoma. The study will also investigate the pharmacokinetics (study of what the body does to the drug), as well as pharmacodynamics (study of what the drug does to the body), which may provide…
Condition: Cancer / Solid Tumors
Investigator: June Hou, MD
Status: Closed
The study drug (TSR-042) in this study is designed to stop cancer from growing by helping your immune system recognize and fight the cancer. The Study Drug is designed to help your immune system by attaching to a protein called PD-1 and stopping one of the signals that keeps your immune system from recognizing the cancer. This may help your immune system…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug sorafenib which works in a similar way to tivozanib. Tivozanib and sorafenib are both called study medication. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer. This study will…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of avapritinib (also known as BLU-285) in individuals who have been diagnosed with aggressive systemic mastocytosis (ASM), Systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell Leukemia (MCL). Avapritinib is an experimental drug means that is is not yet known if…
Condition: Cancer / Leukemia
Investigator: Monica Bhatia, MD
Status: Closed
The purpose of this study is to compare two different combinations of treatment plans to a standard transplant procedure in order to see whether one or both of them are better at reducing the occurrence and severity of chronic GVHD. The research portion of this study involves manipulation of your stem cell product by removing T-cells, which cause chronic…
Condition: Cancer / Lymphoma
Investigator: Ahmed Sawas, MD
Status: Closed
The purpose of this study is to gather information about the effectiveness and safety of as drug called brentuximab vedotin when given in combination with another drug called bendamustine for Hodgkin Lymphoma. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is being done to test the safety and efficacy of immunotherapy based treatment combinations in patients with metastatic non-small cell lung cancer. Participants will be assigned to one of two groups, Cohort 1 or Cohort 2. Each cohort will be split into Stage 1 and Stage 2 phases.
Condition: Cancer
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test the safety of the investigational study drug CB-839 when used in combination with radiation therapy and temozolomide chemotherapy. This study tests different doses of CB-839 to see which dose is safer for people. There will be up to 40 people taking part in this study. Another purpose of this study is to test magnetic…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to learn whether IDH305 is safe and can have possible benefits for people diagnosed with glioma, cholangiocarcinoma, acute myeloid leukemia (AML), chondrosarcoma or other types of solid tumors and have IDH1R132-mutant tumors cancers that have the IDH1R132 mutation and are not getting better after treatment with currently…
Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
You are being asked to participate in this study because you have a neuroendocrine tumor that has spread to your organs. You may or may not have had prior treatment for your neuroendocrine tumor. The purpose of this study is to determine if a drug called entinostat has efficacy in shrinking neuroendocrine tumors. People who usually have metastatic…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
This study is for patients with metastatic or locally advanced soft tissue sarcoma (STS) who are not amenable to treatment with surgery or radiotherapy with curative intent. Patients will be treated with doxorubicin plus olaratumab versus doxorubicin plus placebo intravenously for 8 cycles. Patients without disease progression will be allowed to continue…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is an exploratory biopsy sample study. Its purpose is to better understand why your metastatic cancer has progressed and stopped responding to checkpoint inhibitors. The information gained from this study may be valuable for understanding the mechanisms that cause resistance to immunotherapy. Cancers include: bladder cancer, brain and spinal…
Condition: Cancer / Solid Tumors
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to test the efficacy and safety of an experimental drug, demcizumab, when given in combination with pembrolizumab (Arm A of the study). Demcizumab is a humanized monoclonal antibody and was developed to target cancer stem cells. Demcizumab may block the growth of cancer stem cells, in addition to the remaining cancer cells, and…
Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Closed
You are being asked to participate in this research study because you have been diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment. The purpose of this study is to see if changes in 18FDCFPyL (PyL) PET/CT scans before starting your new treatment and after 6 weeks on treatment is associated with…
Condition: Cancer / Bladder Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
The study is part of a research program to assess the efficacy of the drug nab-rapamycin, a biologic mTOR inhibitor. The purpose of the study is to assess the response rate, as well as, the safety of administering nab-rapamycin in combination with gemcitabine directly into the bladder in an effort to treat bladder cancer. The study seeks to determine if…
Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
The purpose of this clinical trial to find out if the investigational medication pembrolizumab in combination with enzalutamide + Androgen Deprivation Therapy (ADT) is safe and works to slow down or stop the growth of metastatic prostate cancer compared to enzalutamide + ADT alone. Pembrolizumab is a type of immunotherapy, which may help the bodys immune…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to look at the effects of treating Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer with the standard treatment or standard treatment in addition to Erlotinib. Subjects will be randomized to one of the two study groups. Subjects will be on the study for up to two years.
Condition: Cancer / Head and Neck Cancer
Investigator: Matthen Mathew, MD
Status: Closed
There are two study questions we are asking in this randomized phase II/III trial based on a blood biomarker, Epstein Barr virus (EBV) deoxyribonucleic acid (DNA) for locoregionally advanced non-metastatic nasopharyngeal cancer. All patients will first undergo standard concurrent chemotherapy and radiation therapy. When this standard treatment is completed…
Condition: Cancer / Breast Cancer
Investigator: Bret Taback, MD
Status: Closed
The purpose of this study is to capture and evaluate clinical data about the long-term safety and effectiveness of Novilasee - a FDA-cleared minimally invasive treatment for benign breast tumors in hopes that tracking and analyzing the safety and effectiveness of Novilase in a real world application will benefit future patients and the breast cancer…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
The primary purpose of this research study is to evaluate the safety, tolerability and maximum tolerated dose of BAY 1143572. Moreover, concentrations of BAY 1143572 as well as of biomarker proteins may provide information about the effects of BAY 1143572, will be determined in blood and tumor tissue.
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look to obtain information on the best dose of the research drug, TAK 079, when administered in combination with other approved multiple myeloma treatments for patients with newly diagnosed multiple myeloma. If you participate you will receive either Arm A (TAK-079 in combination with lenalidomide and dexamethasone) or Arm B (TAK-079 in…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to find out how safe study drug olaratumab given with gemcitabine and docetaxel is for patients and whether olaratumab given with gemcitabine and docetaxel can help patients with advanced or metastatic soft tissue sarcoma (STS).
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
We are doing this study to find out if an investigational drug called CPI-0610 can help with myelofibrosis. An investigational drug is a drug that is not approved for sale in the United States by the Food and Drug Administration (FDA). This study has two groups (arms) one group of patients will be treated with CPI-0610 alone (monotherapy arm) and the other…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The main goals of this study are to evaluate the safety of the combination of the study drug radium-223 dichloride plus bortezomib and dexamethasone and to determine the optimal dose of radium-223 dichloride to be used in combination with bortezomib and dexamethasone. Radium-223 dichloride has been approved in some countries for treatment of patients with…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this research study is to learn more about adding the drug ADI-PEG 20 to a standard treatment regimen called gem-tax (the chemotherapy drugs gemcitabine and docetaxel) for subjects with bone and soft tissue sarcoma, and how the addition of ADI-PEG 20 affects the tumors response to treatment and the side effects you experience.
Condition: Cancer
Investigator: Antonio Fojo, MD, PhD
Status: Closed
This study is for patients with advanced cancers such as gastroenteropancreatic or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung. This research study tests whether an experimental drug called PEN-221 may help people with before mentioned cancers. It is thought that PEN-221 might…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to determine if the experimental treatment, axicabtagene ciloleucel in combination with utomilumab, is safe and effective in treating individuals with Large B-cell Lymphoma. Axicabtagene ciloleucel is manufactured using your own blood cells. Utomilumab is a molecule (protein) which interacts with a specific region…
Condition: Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find out if the study treatment called RO7198457 (PCV) can be safely given to patients with cancer. PCV is a personalized cancer vaccine. Participants will either received PCV alone or in combination with atezolizumab.
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
The purpose of this study is to find out if the study drug, HE4 has the potential to improve performance of biomarker CA 125 to determine recurrence of epithelial ovarian cancer before detecting the cancer clinically, surgically or through radiological scans. HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female…
Condition: Cancer / Multiple Myeloma
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to test two imaging techniques, one called whole body diffusion weighted magnetic resonance imaging (WB-DWI MRI), and another called F-18 3-deoxy-3-fluorothymidine PET (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with…
Condition: Cancer / Breast Cancer
Investigator: Sheldon Feldman
Status: Closed
The main purpose of this study is to determine the safety and tolerability of Faslodex given directly into thebreast ducts of women with invasive breast cancer or Ductal Carcinoma In Situ (DCIS). This study is for women who have been diagnosed with invasive breast cancer or DCIS. DCIS is the presence of abnormal cells inside a milk duct in the breast, and…
Condition: Cancer / Leukemia
Investigator: Azra Raza, MD
Status: Closed
The purpose of the study is to evaluate the efficacy and safety of imetelstat for the treatment of patients with myelodysplastic syndrome (MDS). All patients participating in Part 1 of this study will get 7.5 mg/kg of imetelstat as a 2-hour intravenous infusion once every 4 weeks. The dose of imetelstat may be increased, held or decreased depending on how…
Condition: Skin Cancer / Melanoma
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this study is to find out more about the Amgen agent called talimogene laherparepvec in people with advanced melanoma when given in combination with another drug developed by Merck called pembrolizumab. Melanoma is a type of skin cancer. Advanced melanoma means the tumor is not removable by surgery or has spread to other parts of the body.
Condition: Skin Cancer / Melanoma
Investigator: Larisa Geskin, MD
Status: Closed
The purpose of this study is to determine how effective and safe the immune drug Nivolumab is for patients who have newly diagnosed cutaneous melanoma. Nivolumab is an anti-body, a type of human protein, that is being tested to see if it will allow the body's immune system to work against tumor cells. If you are eligible for the study, you will…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This is a cohort study looking at the effects of anastrozole (an aromatase inhibitor) on patients, and specifically at Aromatose Inhibitor Musculoskeletal Symptoms (AIMSS). The genetic predictors of AIMSS will also be evaluated. Participants will take daily anastrazole and will be followed for 12 months. The study will enroll 35 patients at Columbia…
Condition: Cancer
Investigator: Meghna Trivedi, MD
Status: Closed
The purpose of this study is to try to learn how certain risk factors, such as age, gender, pre-existing conditions, the type of treatment you get for your cancer, and the amount of cancer drugs in your body affect whether you develop the nerve disorder and how bad your symptoms will be. There will be about 1,000 people taking part in this study.
Condition: Cancer / Solid Tumors
Investigator: Fabio Iwamoto, MD
Status: Closed
The purpose of this research study is to test the effectiveness (how well the drug works), safety, and tolerability varlilumab and nivolumab (investigational drugs) together in patients with advanced solid tumors. Varlilumab and nivolumab are antibodies (types of human protein) that are manufactured in a laboratory and are being tested to see if they will…
Condition: Cancer / Breast Cancer
Investigator: Jeffery Ascherman, MD
Status: Closed
The purpose of this study is to assess the performance and ease of use of the AeroDorm Tissue Expander System in women who are undergoing breast reconstruction surgery. This device is for use in women who are having or have had a mastectomy procedure to remove their breast(s) because of breast cancer (or to decrease their risk of breast cancer). The study…
Condition: Cancer
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine the safety and effectiveness of the study drug in patients with Metastatic Epithelioid Hemangioendothelioma (EHE). The study drug is called trametinib. Trametinib could shrink your cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by at least 30% compared…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The purpose of this study is to test the safety and effectiveness of an experimental medication, FT-2102, in the treatment of acute myeloid leukemia or myelodysplastic syndrome. Patients will receive either FT-2102 alone or in combination with cytarabine or azacitidine, an approved drug commonly used in the treatment of AML and MDS. Subjects will remain on…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 2 study to determine the efficacy and safety of Naloxone HCL Lotion 0.5% for the treatment of mycosis fungoides (MF) type of cutaneous T-cell lymphoma (CTCL). Selected subjects will have the study drug applied to determine its effect on reducing itchiness and any potential side effects. Naloxone has previously been approved for direct blood…
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to evaluate the safety and effectiveness of a new combination treatment involving two drugs: selinexor and ixazomib, for the treatment of dedifferentiated liposarcoma, malignant peripheral nerve sheath tumor, alveolar soft part sarcoma and Ewing sarcoma. The primary objective of the study is to determine the maximum tolerated…
Condition: Cancer / Lung Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to compare the effects, good or bad, of drugs alectinib and crizotnib on patients with lung disease to find out which is better for patients with a special type of non-small cell lung cancer (NSCLC) that is called anaplastic lymphoma kinase (ALK)-positive NSCLC. In this study, participants will receive either alectinib or…
Condition: Cancer / Leukemia
Investigator: Joseph Jurcic, MD
Status: Closed
The main purpose of this study is to see how effective an investigational new drug (tipifarnib, the study drug) is to treat myelodysplastic syndrome (MDS). "Investigational" means that tipifarnib has not yet been approved by regulatory authorities such as the United States Food and Drug Administration (FDA) for use outside of clinical trials. You…
Condition: Cancer / Solid Tumors
Investigator: Richard Carvajal, MD
Status: Closed
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06650808, when given as a single agent and to find the best dose for treating cancer. Prior to this study, PF-06650808 has never been given to people. PF-06650808 is known as an antibody drug conjugate. A toxic agent is chemically linked to an antibody.…
Condition: Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to find out whether the drug talimogene laherparepvec in combination with another drug atezolizumab is safe for people with triple negative breast cancer or colorectal cancer with liver metastases and whether this drug combination causes any side effects.
Condition: Cancer
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to measure how often financial problems happen in patients with chronic lymphocytic leukemia or multiple myeloma, using questionnaires that collect information about finances and quality of life. In order to get a full picture of the financial impact of chronic lymphocytic leukemia and multiple myeloma, we also want to collect…
Condition: Cancer / Solid Tumors
Investigator: Gary Schwartz, MD
Status: Closed
This is a Phase 2-3 study evaluating the effects of selinexor in patients with advanced unresectable dedifferentiated liposarcoma (DDLS). This study drug selinexor works by trapping tumor suppressing proteins within the nucleus of the cells and thus causing the cancer cells to die or stop growing. Selinexor has previously been tested in humans to define a…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (pharmacokinetics). INCB059872 is a…
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
This study is being done to see how safe an investigational drug (LY3039478) is and how well it will work to help people with advanced or metastatic cancer including solid tumors or lymphoma (cancerous growth of lymphoid tissue) including chronic lymphocytic leukemia (CLL blood cell cancer). The primary purpose of your participation in this study is to help…
Condition: Cancer / Solid Tumors
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to find out what effects nivolumab or nivolumab given in combination with ipilimumab have on you and your cancer given the presence of genetic biomarkers (POLE and POLD1). This study will also look at the side effects of these two new immunotherapy drugs.
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This purpose of this study is to determine whether the tumor cells of lung cancer patients contain changes to the DNA sequence of two proteins found on the cells surface- ALK and EGFR. If the tumor contains changes to the DNA of one of these proteins, the patient may be invited to participate on a trial that will look at drugs which may target tumors that…
Condition: Cancer / Prostate Cancer
Investigator: Charles Drake, MD
Status: Closed
We are doing this study to test a drug called MGD009. MGD009 is like an antibody, which is a protein in your blood that helps get rid of germs in your body. MGD009 is made to attach to cancer cells and to T-cells, which are a part of your immune system. Certain T cells have the ability to kill other cells, including cancer cells. By attaching to cancer…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
You are being asked to take part in this study because you have been diagnosed with Myeloproliferative neoplasm (MPN) Associated Myelofibrosis (your disease) and have received ruxolitinib. The purpose of this study is to confirm how well this study treatment works to reduce your spleen volume, spleen size, what effect the study treatment has on you and…
Condition: Skin Cancer / Squamous Cell Carcinoma
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of study drug MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 and tremelimumab combination therapy in the treatment of patients with recurrent or metastatic PD-L1-negative squamous cell carcinoma of the head and neck who have progressed during or after treatment with…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when…
Condition: Cancer / Sarcoma
Investigator: Gary Schwartz, MD
Status: Closed
The purpose of this study is to determine if the study drug toripalimab is safe, to determine future doses to give to patients with cancer, and to measure the amount of toripalimab in the blood. Up to approximately 240 subjects will be enrolled in Part B. The dose given in Part B will be 240 mg. The dose was chosen based upon safety data obtained from…
Condition: Cancer / Prostate Cancer
Investigator: Edward Gelmann, MD
Status: Closed
The purpose of this study is to compare the clinical benefit (i.e., does it help to improve or slow down the cancer) of adding study drug JNJ-56021927 to combined treatment of abiraterone acetate plus prednisone to treat patients with metastatic Castration-resistant Prostate Cancer (mCRPC). This study will also evaluate the possible side effects of study…
Condition: Cancer
Investigator: Emerson Lim, MD
Status: Closed
This is the first study in humans for an investigational drug called CX-2009. CX-2009 is a Probody therapeutic containing a masked antibody (an antibody is a protein naturally occurring in the human body to fight infections and in some cases tumors) attached to a maytansine derivative (a cancer killing therapy). The study is being done to look at the…
Condition: Cancer / Leukemia
Investigator: Daniel Lee, MD
Status: Closed
You are being asked to take part in this study because you have acute myeloid leukemia (AML) that has come back after initial treatment (relapsed) with venetoclax combination therapy or because you did not get a complete response from your initial treatment (refractory) with venetoclax combination therapy. The purpose of this research study is to determine…
Condition: Cancer
Investigator: Joel DeCastro, MD, MPH
Status: Closed
This study is designed to obtain information on the safety and the effectiveness of an experimental drug called Vicinium when it is given to human subject(s)/participant(s) with bladder cancer that has not spread to the muscle of the bladder. Vicinium is part of an antibody connected to a protein that can kill cells. The protein is a modified pseudomonas…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Closed
The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after a 3 day course of chemotherapy, is safe and effective in treating relapsed or refractory (r/r) indolent non-Hodgkin B-cell lymphoma (iNHL). KTE-C19 is made from white blood cells that are removed from the individual. A virus (retrovirus) is…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
Tomography (DOT), can help predict how well patients respond to a pre-surgical therapy. This imaging technique uses light to create 3D maps of the blood, fat, and water content of the breast. Based on these measurements taken over 2 time points during therapy (before and after), we will try to determine if this new imaging technique can use early…
Condition: Cancer / Lung Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
The purpose of this study is to compare the effects of using crizotinib (also known as Xalkori) after completion of surgery, and in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer patients versus placebo. Participants will be randomized to crizotinib or placebo. Participants will take crizotinib/placebo…
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors (Non-small Cell Lung Cancer)
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
This research study is being done to test the combination of two new drugs, GSK3359609 and Tremelimumab, in certain cancers. These two drugs are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. There are two parts to this study. Part 1 determines the best dose for the study drugs and part 2 compares…
Condition: Cancer / Skin Cancer
Investigator: Sewanti Limaye, MD
Status: Closed
The purpose of this study is to examine the effects of KPT-330 on patients with an advanced form of skin cancer called Squamous Cell Cancer (SCC) of the head and neck, lung, or esophagus. The study drug KPT-330 is an investigational drug that
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab may help…
Condition: Cancer / Gynecologic Cancer
Investigator: Ana Tergas, MD
Status: Closed
The main aim of this clinical trial is to know the effects (good or bad) that study drug lurbinectedin (PM01183), has on women with ovarian cancer. Lurbinectedin (PM01183), is an investigational drug. This means that the drug has not been approved by the Food and Drug Administration (FDA) for medical use in patients, but has only been approved for use in…
Condition: Cancer / Liver Cancer
Investigator: Elizabeth Verna, MD
Status: Closed
Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have; learn more about how…
Condition: Cancer / Head and Neck Cancer
Investigator: Matthen Mathew, MD
Status: Closed
The purpose of this study is to study ADU-S100 and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study aims to evaluate how safe and effective this drug combination is at treating your cancer. These drugs are thought to work by interacting with your immune system to in order to more effectively…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work…
Condition: Cancer / Lung Cancer
Investigator: Brian Henick, MD
Status: Closed
The purpose of this study is to determine the doses of RO7121661 that can be administered safely to patients and what the side effects of RO7121661 are. In addition, how RO7121661 affects your body and, in particular, your tumor will be measured. The study also aims to investigate if RO7121661 can slow down or stop the growth of tumors in patients with…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
This study is for women with breast cancer who will be undergoing lumbar puncture to evaluate for the presence of leptomeningeal metastasis, a complication in which the cancer spreads to the membranes (meninges) surrounding the brain and spinal cord. This condition is typically diagnosed by examining the cerebrospinal fluid obtained from the lumbar puncture…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
HE4 (Human Epididymis Protein 4) is a biomarker expressed in the normal lining of the female genital tract and breast. We are doing this research study to if HE4 is an indicator of treatment response during initial therapy for Primary Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers. For this we will collect blood at specific intervals.…
Condition: Cancer / Lung Cancer
Investigator: Catherine Shu, MD
Status: Closed
The purpose of this study is to look at whether the combination of MEDI9447 and osimertinib or MEDI9447 and AZD4635 will improve the outcome in subjects with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC).
Condition: Cancer / Lung Cancer
Investigator: Balazs Halmos, MD
Status: Closed
The purpose of this study is to find out whether the drug, ruxolitinib, is effective, tolerable and safe in combination with two chemotherapy medicines called pemetrexed and cisplatin. The study will test if this combination has beneficial effects in people diagnosed with certain types of non-small cell lung cancer. Only participants with Stage IIIB,…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is research study for patients who have been newly diagnosed with Multiple Myeloma (MM). Their previous treatments have not been successful and their cancer is progressing. The purpose of this research study is to see if the study drug selinexor (KPT-330) has any effects against their cancer. This study combines the use of two drugs, selinexor (KPT-…
Condition: Cancer / Prostate Cancer
Investigator: Sven Wenske, MD
Status: Closed
The goal of this study is to evaluate how the results of a novel laboratory developed and validated urine test which predicts the likelihood of high grade prostate cancer will impact the decision on whether you will have a prostate biopsy to rule out prostate cancer. Approximately 1,000 subjects will be enrolled in this study. The study is expected to last…
Condition: Cancer / Leukemia
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of the study is to see if a combination of idelalisib and BI 836826 can help control patients with Chronic Lymphocytic Leukemia (CLL) without serious side effects.
Condition: Cancer / Breast Cancer
Investigator: Allison Borowski, MD
Status: Closed
We are currently recruiting women to TMIST, a clinical trial that will help us develop strategies that tailor breast cancer screening to the risks of individual women. This is a screening trial. The purpose of this trial is to determine if tomosynthesis (3-D) mammography detects breast cancer at earlier stage than current method of 2-D digital mammography.
Condition: Cancer / Sarcoma
Investigator: Matthew Ingham, MD
Status: Closed
The purpose of this study is to learn about the effects, safety, and proper dosage of tazemetostat in combination with doxorubicin for the treatment of soft tissue sarcoma. Doxorubicin is a common therapy for soft tissue sarcoma, but is not FDA approved in combination with tazemetostat. This study treatment combination may suppress or prevent tumor growth…
Condition: Cancer
Investigator: Francis Gress, MD
Status: Closed
The study aims to assess the effect of porfimer sodium with PDT administered with medical standard ofcare compared to medical standard of care alone on the overall survival time of patients with bile duct cancer and its effect on cholestasis (blocked bile flow), time-to-treatment failure, performance status, and health-related quality of life.
Condition: Cancer / Lung Cancer
Investigator: Craig Blinderman, MD, MA
Status: Closed
Research has shown that early involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients and their loved ones experience with their cancer. This team is called palliative care, and consists of…
Condition: Cancer / Breast Cancer
Investigator: Kevin Kalinsky, MD, MS
Status: Closed
The purpose of this study is to determine the effects of combining metformin and atorvastatin treatment in patients with newly diagnosed breast cancer during the interval between breast biopsy and surgery. Metformin is a common treatment for patients with diabetes, and atorvastatin is a common therapy for elevated cholesterol. We will examine the effects of…
Condition: Cancer / Breast Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to gather information on the safety of TH-302 and its effect on patients with HER2+ breast cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about this specific cancer such as the level of oxygen that is present. This may…
Condition: Cancer / Gastrointestinal
Investigator: Matthew Ingham, MD
Status: Closed
Deciphera Pharmaceuticals, LLC., the Sponsor of this study, is developing a drug called DCC-2618 to treat Gastrointestinal Stromal Tumors (GIST) that are growing because of changes in specific genes. Genes are the instructions that tell a part of your body called a cell what to do. Cancer changes the genes so that the instructions are no longer correct. DCC…
Condition: Cancer
Investigator: Nicole Lamanna, MD
Status: Closed
The purpose of this study is to find out if the study drug zanubrutinib is safe and can help subjects who have Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This will involve comparison of two drugs, zanubrutinib and ibrutinib, in treating CLL/SLL by: (1)Testing how effectively the drug zanubrutinib controls CLL/SLL and (2)…
Condition: Cancer
Investigator: Naiyer Rizvi, MD
Status: Closed
This study is for individuals with advanced cancers. Only patients with non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer (CRC), bladder cancer, ovarian cancer, esophageal cancer, gastric cancer, or renal cell carcinoma will be enrolled. The purpose of the study is to determine the best doses of…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma (MM) by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to…
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to find the dose of imetelstat that best treats myelofibrosis. (A doseis a measured amount of a drug taken at one time.) The effects of imetelstat on myelofibrosis as well as any side effects will be explored.
Condition: Cancer / Leukemia
Investigator: Mark Heaney, MD, PhD
Status: Closed
The purpose of this study is to provide samples for biomarker testing for the different MPD-RC treatment studies. As part of the treatment study you currently participating in, this is an additional research study in which you we will ask for you to donate blood and/or bone marrow samples, two nail clippings, and buccal (cheek) swab. In order to…
Condition: Cancer / Lymphoma
Investigator: Larisa Geskin, MD
Status: Closed
This is a phase 3 clinical trial to determine the efficacy of topical SGX301 (synthetic hypericin) in combination with visible light therapy on cutaneous T-cell lymphoma (CTCL). Selected subjects can participate in 3 cycles each consisting of a 6 week treatment period where a chosen lesion will be treated with the study ointment (twice a week) followed by…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE